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Dystrophin is the gene product that is affected in Du-
chenne muscular dystrophy (DMD). Antibodies
against dystrophin were used to study the protein in
muscle fibers of carriers of the gene. The results
DUCHENNE MUSCULAR DYSTROPHY (DMD)
is the most common ofthe childhood dystrophies. It
is inherited as an X-linked recessive disorder and the
incidence is approximately 1 in 3000 live male bir-
ths.t Recently, dystrophin, a newly recognized mus-
cle-specific protein was identified as the affected gene
product in DMD.2 In electrophoretic studies, the
protein was missing in patients with DMD and
showed abnormal molecular weight in patients with
Becker muscular dystrophy.2'3 In immunohisto-
chemical studies, dystrophin has been localized to
the sarcolemma of normal muscle fibers. In DMD
patients and in mice with X-linked muscular dystro-
phy (mdx), the sarcolemmal immunostain was either
absent or markedly reduced in frozen sections of
muscle samples.4'5
We have now studied dystrophin in DMD carriers
using anti-dystrophin antibodies in combination with
immunofluorescence. The results showed that DMD
carriers have two populations of fibers: normal and
dystrophin-deficient.
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showed that DMD carriers have normal and dystro-
phin-deficient fibers. Dystrophin immunohistochem-
istry may be helpful for the detection ofDDMD carriers.
(AmJ Pathol 1988, 133:440-445)
Materials and Methods
We have studied muscle biopsies from nine obligate
carriers and two possible carriers of the DMD gene.
Carriers were considered to be genetically obligate
cases if they had two or more affected sons or one
affected son and another affected maternal relative.
Possible carriers were mothers of one isolated case of
DMD. Four obligate and one possible carrier showed
clinical evidence ofproximal muscle weakness (mani-
festing carriers). Ages of the 11 women ranged from
19 to 63 years. Serum CK values ranged from 48 to
51 1 IU (normal < 50 IU). Muscle biopsies were frozen
in liquid nitrogen-cooled isopentane, sectioned for di-
agnostic purposes, and stored in liquid nitrogen until
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Figure 1-Binding of anti-dystrophin in normal human muscle. a-Immunostaining is seen at the sarcolemma (arrows) of all muscle fibers.
Control section incubated with nonimmune serum shows lack of stain at the surface of the fibers. x200
the time ofthis study. As controls, we used specimens
from four women (ages 16, 20, 25, and 32 years) who,
after full diagnostic studies at Columbia-Presbyterian
Medical Center, were deemed to be free ofneuromus-
cular disease. All human samples were obtained in ac-
cordance with the guidelines ofthe Columbia Univer-
sity Human Subjects Committee.
We used the original polyclonal antibodies of
Hoffman et a13 raised against fusion proteins (a gift of
Drs. L. M. Kunkel and E. P. Hoffman). The sheep
antisera against the 60 kd antigen used in this study
reacted only with dystrophin in Western analysis of
SDS-solubilized muscle tissue, indicating the mono-
specificity ofthe antibody preparation.3'5
For immunohistochemistry, 4 A-thick sections
from normal andDMD carrier muscle were placed on
the same coverslip and incubated with anti-dys-
trophin diluted 1:1000 in phosphate-buffered saline
(PBS) containing 1% bovine serum albumin (BSA).
After 2 hours, the sections were washed 3 times in
PBS, incubated for 20 minutes with biotinylated anti-
sheep IgG (Amersham Corporation, Arlington
Heights, IL; 10 ug/ml), and washed 3 times in PBS.
The sections were incubated for 1 hour with streptavi-
din-fluorescein (Amersham Corporation; 10 ,ug/ml)
(1:250), washed 3 times with PBS, and mounted with
50% glycerol in PBS.5 Control sections were incubated
with nonimmune serum and with PBS containing 1%
BSA. To evaluate morphologic alterations ofthe mus-
cle fibers, additional sections were stained with hema-
toxylin and eosin (H & E), modified trichome, and
myofibrillar ATPase pH 9.4.5 The sections were ex-
amined and photographed with a Zeiss II photomicro-
scope equipped with epi-illumination.
For evaluation of dystrophin immunostain at the
sarcolemma, portions of five different fascicles from
each sample were photographed using a Xl16 objec-
tive. The negatives were then projected onto paper to
determine the number of fibers surrounded by a con-
tinuous layer of immunofluorescence at the sarco-
lemma and the number of fibers with absent or mark-
edly diminished immunostain at the cell surface. A
total of 200-220 fibers were counted for each sample
and the results were expressed as a percentage.
Results
In cross-sections of the four normal biopsies, dys-
trophin was localized at the sarcolemma of the fibers.
The cell surface of each muscle fiber showed a thin
and continuous layer of immunofluorescence and
there was no immunostain of intracellular compo-
nents (Figure la). We saw no staining of capillaries or
interstitial cells and there were no muscle fibers that
lacked dystrophin. Examination of control sections
incubated with nonimmune serum showed no reac-
tion at the sarcolemma (Figure lb).
In frozen sections from the five manifesting DMD
carriers, dystrophin immunostain was lacking or mark-
edly reduced in a population of fibers that formed scat-
tered small groups throughout the samples (Figure 2a).
Except for small discontinuities of immunostain at the
surface ofoccasional large fibers, the reaction at the sar-
colemma was present and appeared continuous in the
other muscle fibers. Adjacent sections from these sam-
ples stained with H & E showed marked variation in
fiber size, increased central nuclei, occasional regenerat-
ing fibers, scattered groups of small muscle fibers, and
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Figure 2-Binding of anti-dystrophin in a muscle section from a manifesting DMD carrier. a-The immunostaining at the sarcolemma is markedly reduced
(arrows) in two groups of fibers. Although reduced the amount of immunofluorescence observed at the sarcolemma of these fibers appeared greater than
the background staining noted in control sections incubated with nonimmune serum. b-Adjacent section stained with H-E shows that muscle fibers
with reduced dystrophin (arrows) do not appear to be degenerating or regenerating. X250
focal increase of connective tissue. The groups of small
fibers did not appear to be regenerating or degenerating
(Figure 2b) and with stains for myofibrillar ATPase pH
9.4, the dystrophin-deficient groups comprised both
type I and type II fibers.
In frozen sections from four obligate but asymp-
tomatic DMD carriers, there was lack or marked re-
duction of dystrophin immunostain at the sarco-
lemma of isolated muscle fibers (Figure 3a). Only
rarely were these fibers adjacent, forming groups of
two or three fibers (Figure 3b). Adjacent sections from
these samples stained with H & E showed mild varia-
tion in fiber size, increase central nuclei, and occa-
sional hyaline fibers.
In muscle sections from one obligate and one possi-
ble DMD carrier, no dystrophin-deficient fibers were
Figure 3-Binding of anti-dystrophin in a muscle section from an asymptomatic DMD carrier. a-One isolated fiber (star) shows lack of immunostain at
the sarcolemma. X260 b-Two adjacent fibers (stars) show reduced dystrophin at the sarcolemma. The faint immunofluorescence noted in these fibers
was greater than the background seen in sections incubated with nonimmune serum. x350
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Figure 4-Binding of anti-dystrophin in longitudinal sections. a-Normal human muscle shows continuous immunostain at the sarcolemma. b-
Section from a DMD carrier shows large gaps (arrows) in dystrophin immunostain. c-Another section shows (arrows) punctuated and discontinuous
immunostain in one dystrophin-deficient fiber. x2000
detected. Adjacent sections from these specimens
stained with H & E showed mild variation in fiber size
and few central nuclei.
Longitudinal sections from normal muscle showed
continuous dystrophin immunostain at the sarco-
lemma of the fibers (Figure 4a). In manifesting and
nonmanifesting DMD carriers the dystrophin-defi-
cient fibers showed either large gaps in the immuno-
stain (Figure 4b) or a punctuated and discontinuous
immunostain ofthe sarcolemma (Figure 4c).
To evaluate the number of dystrophin-deficient fi-
bers, we counted in cross-sections only those fibers
showing lack, or marked reduction of immunostain
(Figure 3a) and those in which more than 40% of the
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sarcolemma remained unstained on map-reading of
the projected negatives. The cutoff limit of 40% was
chosen because rare fibers at the periphery ofthe sam-
ples in both carriers and normals showed gaps of im-
munostain that comprised up to 30% ofthe surface of
the fiber. The invariably peripheral location of these
fibers and the fact that they were seen in both normal
and carriers suggest that these gaps of immunostain
were due to mechanical damage during handling of
the specimens. When the dystrophin-deficient fibers
were counted and averaged for all 11 carriers, 12% of
all fibers examined showed dystrophin deficiency. In
individual carriers, the proportion of fibers with al-
tered dystrophin immunostain ranged from 0-32%,
and the proportion was higher in the five manifesting
carriers (18.2, 22.4, 27.1, 28.3, and 32.2%) than in the
six asymptomatic ones (0.0, 0.0, 2.1, 2.5, 4.1, and
4.3%). In the controls, fibers lacking dystrophin im-
munostain at the sarcolemma were never observed.
Discussion
The high incidence ofDMD, the hardship the dis-
ease imposes, and the potential transmission by
healthy females make detection ofheterozygous carri-
ers one ofthe major goals in the prevention ofthe dis-
ease.
For many years, tests used for identification of
DMD carriers have included determinations ofserum
CK levels, electromyography, and morphologic eval-
uation ofmuscle biopsy.6 These tests are far from per-
fect however, because they provide information about
secondary phenomena, not the primary abnormality
in DMD. Another difficulty inDMD carrier detection
stems from the X-linked nature ofthe disease, because
X chromosome inactivation results in greater vari-
ability of heterozygote phenotypes than in autosomal
disorders. This variability ofexpression may facilitate
carrier detection in those heterozygotes that show
clinical abnormalities. On the other end, a proportion
of carriers will be difficult to detect by traditional
methods and will require tools capable of identify-
ing a double population of muscle cells, or DNA
analysis.7'8
This study used antibodies directed against the
DMD gene product dystrophin to study the protein in
individual fibers from carriers of the gene. In trans-
verse sections ofnormal human muscle, the immuno-
cytochemical reaction for dystrophin is evident in the
sarcolemma ofall muscle fibers.4'5 In longitudinal sec-
tions, the protein is distributed homogeneously in the
sarcolemma, all along the length of the fiber. In pa-
tients with typical DMD, the protein is either totally
absent or there are only faint nonhomogeneous spots
ofimmunoreactive material in the sarcolemma.4'5
We have now found that muscle from carriers of
the gene contain two populations of fibers, some con-
taining dystrophin and others with partial deficiency
of dystrophin as evaluated by the criteria adopted by
us. The proportion of dystrophin-deficient fibers was
higher (18-32%) in manifesting carriers than in
asymptomatic carriers, where the proportion of dys-
trophin-deficient fibers was 0-4.3%.
These results are compatible with the Lyon hypoth-
esis stating that there is random inactivation of the X
chromosome early in development.9"0 InDMD carn-
ers, the formation of myotubes is thought to result
from the random fusion of two populations of
myoblasts, one carrying the mutated X-chromosome,
the other containing the normal X. The proportion of
nuclei containing the mutated DMD gene within any
muscle fiber of a carrier will determine whether the
fiber will have a normal amount, partial deficiency or
total lack of dystrophin at the sarcolemma. Our data
provide graphic evidence of something long believed
by clinicians-that manifesting carriers of the DMD
gene probably have a higher proportion of affected
muscle fibers than asymptomatic carriers. The results
suggest that symptoms may result even when fewer
than halfofthe fibers are affected.
Dystrophin immunohistochemistry may be useful
for diagnosis, but we have not yet established specific-
ity or reliability. It would be helpful ifa simple histo-
logic test ofthis kind were available, because although
DNA diagnosis of the carrier state is currently the
most reliable, this method is expensive, time-consum-
ing, and not effective in all families.7 Quantitative
analysis of dystrophin must still rely on gel electro-
phoresis and this method may not be sensitive enough
to detect a small population of dystrophin-deficient
fibers. Further testing of the immunocytochemical
method therefore seems warranted.
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